A Clinical Laboratory Improvement Amendments (CLIA) laboratory performed NGS-based diagnostic genomic profiling which identified this tumor as the first reported case of the KIAA1549-BRAF fusion in a PTEN null background as a driving genomic alteration susceptible to targeted therapy. Here, KIAA1549 is linked to neoplasm.